Cushing's disease: cross-border specialty drug access for international patients

Quick orientation

Cushing's disease (ACTH-secreting pituitary adenoma) is rare, with annual incidence estimated at 1.2 to 2.4 cases per million people per year. Endogenous Cushing's syndrome overall is somewhat more common.

Typical age of onset. Most commonly diagnosed in adults aged 25 to 50.

Severity tiers. Untreated, Cushing's disease causes substantial cardiovascular, metabolic, bone, and psychiatric morbidity. Transsphenoidal surgery is first-line; medical therapy is used when surgery is not possible or has failed.

Why specialty drugs for Cushing's disease are hard to access internationally

Several medical therapies for Cushing's are available, but newer agents such as Isturisa (osilodrostat), Recorlev (levoketoconazole), and Korlym (mifepristone) are not all registered in MENA or South Asia. International access typically requires a treating endocrinologist who is comfortable monitoring cortisol dynamics on therapy.

Treatments approved by the FDA

• Isturisa (osilodrostat) — FDA approval: 2020. Mechanism: 11-beta-hydroxylase inhibitor. Route: Oral twice daily. US WAC ballpark: Approximately USD 110,000 to 180,000 per year.
• Recorlev (levoketoconazole) — FDA approval: 2021. Mechanism: Steroidogenesis inhibitor (single enantiomer of ketoconazole). Route: Oral twice daily. US WAC ballpark: Approximately USD 200,000 per year.
• Korlym (mifepristone) — FDA approval: 2012. Mechanism: Glucocorticoid receptor antagonist. Route: Oral once daily. US WAC ballpark: Approximately USD 300,000 to 350,000 per year at higher doses.

Cross-border pathways used for Cushing's disease

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Compassionate Use
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm ACTH-dependent versus ACTH-independent disease and exclude ectopic ACTH syndrome.
• Document surgical history and response.
• Cortisol monitoring (24-hour urinary free cortisol, late-night salivary cortisol) is essential.
• Watch for adrenal insufficiency on steroidogenesis inhibitors.
• Endocrinologist co-management is required.

Common questions

Can medical therapy cure Cushing's disease?

Medical therapy controls cortisol but does not cure the underlying tumor. Surgery and radiation remain definitive.

How do I choose between agents?

Choice depends on cortisol levels, tumor characteristics, glucose tolerance, and patient factors. Your endocrinologist decides.

Are these drugs available locally?

Some are; some are not. Registration varies by drug and country. We confirm by destination.

What documents are required?

Treating endocrinologist's prescription, recent cortisol workup, and surgical and radiation history.

How is dosing adjusted?

Steroidogenesis inhibitors are titrated to cortisol levels. Regular labs are required.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Cushing's disease, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Cushing's disease

Reserved for you.